Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long Term Safety And Efficacy Study Of Pregabalin (Lyrica) In Subjects With Generalized Anxiety Disorder [ESTUDIO DE SEGURIDAD Y EFICACIA A LARGO PLAZO DE PREGABALINA EN SUJETOS CON TRASTORNO DE ANSIEDAD GENERALIZADA]

Trial Profile

Long Term Safety And Efficacy Study Of Pregabalin (Lyrica) In Subjects With Generalized Anxiety Disorder [ESTUDIO DE SEGURIDAD Y EFICACIA A LARGO PLAZO DE PREGABALINA EN SUJETOS CON TRASTORNO DE ANSIEDAD GENERALIZADA]

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Dec 2013

At a glance

  • Drugs Pregabalin (Primary) ; Lorazepam
  • Indications Generalised anxiety disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Aug 2012 Planned number of patients changed from 600 to 794 as reported by European Clinical Trials Database.
    • 09 Apr 2012 Actual patient number changed from 600 to 621 as reported by ClinicalTrials.gov
    • 09 Apr 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top